Patent Grant
8467843
1. Field of the Invention
Embodiments of the invention are directed to an optical sensor for detecting an analyte, preferably glucose. In preferred embodiments, the sensor comprises an optical fiber having a fluorescence chemistry disposed along the distal region of the fiber, more preferably located between the distal end of the fiber and an atraumatic tip.
2. Description of the Related Art
Hyperglycemia and insulin resistance are common in critically ill patients, even if such patients have not previously had diabetes. In these situations, glucose levels rise in critically ill patients thereby increasing the risk of damage to a patient's organs. Further, studies have shown that normalization of blood glucose levels with insulin therapy improves the prognosis for such patients, thereby decreasing mortality rates.
More recent scientific evidence confirms that dramatic improvements in the clinical outcome of hospitalized Intensive Care Unit (ICU) patients can result from tight therapeutic control of blood glucose to normal ranges. These studies indicate that Tight Glycemic Control (TGC) of ICU patients may reduce mortality by as much as 40%, and significantly lower complication rates. In these situations, it is necessary to accurately, conveniently and continuously monitor blood sugar in a real-time device specifically designed to meet the challenging needs of the ICU environment. Researchers at Johns Hopkins University estimate that TGC can save as many as 150,000 lives and reduce U.S. healthcare costs by as much as $18 billion annually.
Performing TGC requires continuous and accurate monitoring of a patient's blood glucose levels. Thus, there is a need for a real-time glucose monitoring system that is adapted to meet the needs of ICU patients.
A sensor for detecting an analyte concentration in a blood vessel is disclosed in accordance with an embodiment of the invention. The sensor comprises: an optical fiber with proximal and distal ends; an atraumatic tip portion with proximal and distal ends, wherein the proximal end of the atraumatic tip portion is separated from the distal end of the optical fiber, such that a gap exists between the atraumatic tip portion and the optical fiber; a rod with proximal and distal ends, wherein the proximal end of the rod is attached to the distal end of the optical fiber, and wherein the distal end of the rod is attached to the proximal end of the atraumatic tip portion, such that the rod traverses the gap and couples the optical fiber to the atraumatic tip portion; a chemical indicator system capable of generating an emission light signal in response to an excitation light signal, wherein the intensity of the emission light signal is related to the analyte concentration, and wherein the chemical indicator system is disposed within the gap; and a selectively permeable membrane disposed over the gap, wherein the sensor is sized for deployment within the blood vessel.
In one variation to the analyte sensor, the chemical indicator system is immobilized within the gap by a hydrogel. In another variation, the sensor further comprises a temperature sensor. The optical fiber preferably has a diameter of between about 0.005 inches and about 0.020 inches. In another variation, the sensor further comprises a reflective region. Preferably, the reflective region comprises a reflective surface of the proximal end of the rod. In one embodiment, the rod may be attached to the optical fiber and atraumatic tip portion by heating. In another embodiment, the rod may be attached to the optical fiber by a reflective or optically clear adhesive.
In variations to the sensor, the shape of the distal end of the atraumatic tip portion may be configured to reduce trauma within the blood vessel. In various embodiments, the shape of the distal end of the atraumatic tip portion may be selected from the group consisting of hemispherical, parabolic, and elliptical. In another variation, the distal end of the atraumatic tip portion is flexible. In another variation, the distal end of the atraumatic tip portion is deformable. The distal end of the atraumatic tip portion may be formed from at least one material selected from the group consisting of plastics, polymers, gels, metals and composites.
The rod may be formed from at least one material selected from the group consisting of metal, metal alloy, plastic, polymer, ceramic, and composite material. In a preferred variation, the rod is formed from stainless steel, titanium, or Nitinol. In one embodiment, the rod is cylindrical. Preferably, the rod diameter is between about 0.002 inches and about 0.010 inches. The rod may be flexible in some embodiments. The rod is stiffer than the optical fiber in some embodiments. In such embodiments, the rod is preferably sufficiently stiff to prevent flexing of the sensor along the gap.
A sensor for detecting an analyte concentration in a blood vessel is disclosed in accordance with another embodiment of the present invention. The sensor comprises: an optical fiber with proximal and distal ends; an atraumatic tip portion with proximal and distal ends, wherein the proximal end of the atraumatic tip portion is separated from the distal end of the optical fiber, such that a gap exists between the atraumatic tip portion and the optical fiber; a hypotube with proximal and distal ends, wherein the proximal end of the hypotube is attached to the distal end of the optical fiber, and wherein the distal end of the hypotube is attached to the proximal end of the atraumatic tip portion, such that the hypotube traverses the gap and couples the optical fiber to the atraumatic tip portion, wherein the hypotube comprises at least one window that opens onto the gap; a chemical indicator system capable of generating an emission light signal in response to an excitation light signal, wherein the intensity of the emission light signal is related to the analyte concentration, and wherein the chemical indicator system is disposed within the gap; and a selectively permeable membrane disposed over the at least one window, wherein the sensor is sized for deployment within the blood vessel. In preferred embodiments, the chemical indicator system is immobilized by a hydrogel within the cavity formed within the hypotube. In further preferred embodiments of the sensor with hypotube, a reflective member is disposed within the sensor. In further preferred embodiments of the sensor with hypotube, a fluorescent member is disposed within the sensor.
A sensor for detecting an analyte concentration in a blood vessel is disclosed according to another embodiment of the present invention. The sensor comprises: an optical fiber with proximal and distal ends; an atraumatic tip portion with proximal and distal ends, wherein the proximal end of the atraumatic tip portion is separated from the distal end of the optical fiber, such that a gap exists between the atraumatic tip portion and the optical fiber; a cage connecting the optical fiber and atraumatic tip portion, wherein the optical fiber is at least partially enclosed within the cage, and wherein the cage has at least one window; a chemical indicator system disposed within the cage, wherein the chemical indicator system is adjacent the window and is separated from analyte by a selectively permeable membrane, and wherein the chemical indicator system is capable of generating an emission light signal in response to an excitation light signal, wherein the intensity of the emission light signal is related to the analyte concentration; and a reference material, wherein the reference material is configured to either reflect a portion of the excitation light signal before the excitation light signal enters the chemical indicator system or to return a second emission light signal, wherein the intensity of the second emission light signal is not related to the analyte concentration.
In another embodiment, a method for measuring glucose concentration is provided. The method comprises transmitting a first light in a first direction through an optical fiber to a glucose sensor, where the glucose sensor comprises a hydrogel cavity having a fluorophore system. At least a portion of the first light is reflected off a reflective surface of the glucose sensor as a second light in a second direction opposite the first direction. A third light is emitted in the second direction. The third light results from the chemical indicator system fluorescing. The method further comprises calculating the glucose concentration, where the glucose concentration is determined by the ratio of the emitted third light to the reflected second light. The ratio is independent of the intensity of the first light.
In another embodiment, a method for measuring glucose concentration is provided. The method comprises transmitting a first light in a first direction through an optical fiber to a glucose sensor, where the glucose sensor comprises a hydrogel cavity having a fluorophore system which is sensitive to glucose as well as a second fluorophore which is glucose insensitive. A second light from the glucose sensitive fluorophore is emitted in a second direction opposite the first direction. A third light from the glucose insensitive fluorophore is also emitted in the second direction. The method further comprises calculating the glucose concentration, where the glucose concentration is determined by the ratio of the emitted second light to the emitted third light. The ratio is independent of the intensity of the first light.
In another embodiment, a system for measuring glucose is provided. The system comprises at least one light source, at least one optical fiber coupled to the light source, any one of the glucose sensors described above coupled to the optical fiber, and a data processing device coupled to the glucose sensor.
In another embodiment, a method for manufacturing a glucose sensor is provided. The method comprises inserting a first end of a rod into an optical fiber, inserting a second end of the rod into an atraumatic tip, surrounding the rod with a hydrogel cavity, and enclosing the hydrogel cavity with a selectively permeable membrane.
In another embodiment, a method for manufacturing a glucose sensor is provided. The method comprises cutting a window in a hypotube, contacting an optical fiber with a first end of the hypotube, and heating the optical fiber, such that the optical fiber swells to fully contact the first end of the rod.
In another embodiment, a sensor for detecting an analyte concentration in a blood vessel is provided. The sensor comprises an optical fiber with a proximal end and a distal end. The distal end of the optical fiber comprises a glucose sensing hydrogel. The glucose sensing hydrogel comprises a first fluorophore, a quencher, and at least one glucose receptor. A reference fiber is adjacent the optical fiber and has a proximal end and a distal end. The distal end of the reference fiber comprises a reference material. The reference material comprises a second fluorophore. A light emitting diode is operably coupled to the glucose fiber and the reference fiber. The light emitting diode sends an excitation light to the glucose fiber and the reference fiber. A glucose signal detector is operatively coupled to the glucose fiber. The glucose signal detector receives a first fluorescent light from the glucose fiber. A reference signal detector is operatively coupled to the reference fiber. The reference signal detector receives a second fluorescent light from the reference fiber.
Various embodiments of optical systems and methods are disclosed herein for determining blood glucose concentrations. The various embodiments preferably share at least two features. First, they involve exciting a chemical indicator system with an excitation light signal and measuring the emission light signal of the indicator system, wherein the indicator system is in contact with the blood and comprises a fluorescent dye operably coupled to a glucose binding moiety-such that the emission light signal generated by the indicator system upon excitation is related to the blood glucose concentration. Second, they involve correcting the blood glucose concentration measurements from the indicator system for potential artifacts due to the optical system, which artifacts are unrelated to the blood glucose concentration. The correction is performed by ratiometric analysis. More particularly, the ratio of emission light signal to a second light signal that is propagated through the optical system, e.g., the excitation light signal or a separate reference light signal, is used for correcting any non-glucose related contributions of the optical system. Where the excitation light signal is used for the ratiometric correction, the sensor preferably includes a reflective surface, e.g., a minor, located somewhere along the sensor, such that at least a portion of the excitation light which has passed through the optical system is reflected back to a detector. Where a separate reference light signal is used, the reference light signal may either be: (1) generated by a separate light source and reflected back to a detector, or (2) generated as a separate emission light signal from a separate dye disposed somewhere along the sensor. Thus, a glucose sensor in accordance with preferred embodiments of the present invention will comprise either a reflective surface or a second dye adapted to emit a reference light signal.
Various structural configurations have been proposed for holding a chemical indicator system in a position, which is: (1) exposed to the blood, (2) disposed within the excitation light path, and (3) for exposing a chemical indicator system to the blood and, for introducing to the indicator system an excitation light signal, for detecting an emission light signal from the indicator system, and for enabling ratiometric correction of glucose determinations for artifacts of the system optics; see in particular 2008/0188725. More particularly, aspects of the present invention relate to improvements and alternative embodiments for generating a reference light signal (as discussed in 2008/0188725), either through various mirror/reflective surface configurations adapted to return a portion of the excitation light signal back to a detector or through generating a separate emission light signal from a separate dye. Aspects of the present invention relate to new and improved configurations for disposing a chemical indicator system within an interrogation light path, wherein the sensor is more robust and exhibits improved patient tolerance.
Optical glucose sensors, such as those described in U.S. Patent Publ. Nos. 2008/0188722, 2008/0188725, 2008/0187655, 2008/0305009, 2009/0018426, 2009/0018418, and co-pending U.S. patent application Ser. Nos. 11/296,898, 12/187,248, 12/172,059, 12/274,617 and 12/424,902 (each of which is incorporated herein in its entirety by reference thereto) typically employ a chemical indicator system disposed at the distal end of an optical fiber, wherein the indicator system is maintained in contact with the blood, such that an excitation light signal sent distally down the fiber causes the chemical indicator system to emit a light signal related to the concentration of glucose.
In certain embodiments, an optical glucose measurement system is disclosed for measuring glucose concentration in blood using one or more glucose-sensing chemical indicator systems. Such indicator systems preferably comprise a fluorophore operably coupled to a glucose binding moiety. Preferably, the glucose binding moiety acts as a quencher with respect to the fluorophore (e.g., suppresses the fluorescent emission signal of the fluorophore in response to excitation light when it associates with the fluorophore). In preferred embodiments, as the glucose binding moiety binds glucose (e.g., as glucose concentrations rise), it dissociates from the fluorophore, which then generates a fluorescent emission signal upon excitation. Accordingly, in such embodiments, the higher the glucose concentration, the more glucose bound by the binding moiety, the less quenching, and the higher the fluorescence intensity of the fluorophore upon excitation.
In certain embodiments, the optical glucose measurement system measures glucose concentrations intravascularly and in real-time through the use of such chemical indicator systems. In certain embodiments, the glucose-sensing chemical indicator systems are immobilized in a hydrogel. The hydrogel may be inserted into an optical fiber such that light may be transmitted through the hydrogel while at least a portion of the hydrogel is in contact with blood. The hydrogel is preferably permeable to blood and analytes, specifically glucose. In certain embodiments, the optical fiber together with the hydrogel comprises a glucose sensor that is placed in a mammalian (human or animal) blood vessel.
Examples of glucose-sensing chemical indicator systems and glucose sensor configurations for intravascular glucose monitoring include the optical sensors disclosed in U.S. Pat. Nos. 5,137,033, 5,512,246, 5,503,770, 6,627,177, 7,417,164 and 7,470,420, and U.S. Patent Publ. Nos. 2008/0188722, 2008/0188725, 2008/0187655, 2008/0305009, 2009/0018426, 2009/0018418, and co-pending U.S. patent application Ser. Nos. 11/296,898, 12/187,248, 12/172,059, 12/274,617 and 12/424,902; each of which is incorporated herein in its entirety by reference thereto.
Light may be transmitted into an optical glucose sensor from a light source. In certain embodiments, the light source is a light emitting diode that emits an optical excitation signal. The optical excitation signal excites the fluorophore system(s), such that the fluorophores emit light at an emission wavelength. In certain embodiments, the fluorophore systems are configured to emit an optical emission signal at a first wavelength having an intensity related to the blood glucose concentration in the blood vessel. In certain embodiments, light is directed out of the glucose sensor such that the light is detected by at least one detector. The at least one detector preferably measures the intensity of the optical emission signal, which is related to the glucose concentration present in the blood. Various optical configurations for interrogating glucose-sensing chemical indicator systems with one or more excitation light signals and for detecting one or more emission light signals from the chemical indicator systems may be employed, see e.g., U.S. Patent Appl No. 12/027,158 (published as 2008/0188725); incorporated herein in its entirety by reference thereto.
Glucose Activity and Tight Glycemic Control
While clinicians have used insulin for decades to regulate glucose levels in diabetics and critically ill patients, determining precise dosages remains a problem. Insulin reduces circulating glucose levels through a series of complex interactions involving a number of hormones and cell types. Dosage protocols for insulin attempt to replicate the physiologic secretion of the hormone by the pancreas. However, administering according to fixed times and algorithms based on blood glucose measurements can only crudely approximate the ability of a healthy individual to continuously adjust insulin production in response to the amount of bioavailable glucose and the needs of the body. Thus, to determine the precise amount of insulin that should be administered to maintain a patient's blood glucose at an appropriate level, it is necessary to have near real-time, accurate measurements of the amount of bioavailable glucose circulating in blood.
Unfortunately, most existing methods for determining blood glucose concentrations fail to provide near real-time, accurate measurements of the amount of bioavailable glucose. Clinicians and diabetic patients typically rely on point-of-care testing that seems to measure glucose concentration in plasma, e.g., using glucometers to read test strips that filter separate plasma from cells in a drop of whole blood. While the results can be available quickly, they vary depending on the patient's hematocrit, plasma protein and lipid profiles, etc., and can often be falsely elevated (See e.g., Chakravarthy et al., 2005 “Glucose determination from different vascular compartments by point-of-care testing in critically ill patients” Chest 128(4) October, 2005 Supplement: 220S-221S). More accurate determinations can be obtained by first separating the cellular components of whole blood. However, this requires separation of the plasma from the cellular components of blood, e.g., by centrifugation. Subsequently, isolated plasma must be stored and/or transported and/or diluted prior to analysis. Storage and processing conditions, e.g., temperature, dilution, etc., will almost certainly perturb the in vivo equilibrium between the bound and free (bioavailable) glucose. Consequently, regardless of the technology subsequently employed for measuring plasma glucose concentration (e.g., glucose oxidase, mass spectrometry, etc.), the measured glucose concentration is likely no longer reflective of the amount of bioavailable glucose in vivo. Therefore, it is not feasible to use plasma glucose measurements for near real-time monitoring and adjustment of a patient's glucose level.
Accordingly, in certain embodiments, the preferred glucose sensors described herein measure glucose “activity” as opposed to glucose concentration. More precisely, glucose activity refers to the amount of free glucose per kilogram of water. In some embodiments, glucose activity can be measured directly using glucose sensors, such as the equilibrium, non-consuming optical glucose measurement systems discussed above, which employ a chemical indicator system to quantify the amount of free, bioavailable glucose, which is in equilibrium between the water compartment of blood (i.e., not associated with cells, proteins or lipids, etc.) and the glucose binding moiety/quencher. The discussion of the sensors that follow will often refer to the physical quantity to be measured as an “analyte concentration”, “glucose concentration” or simply a “concentration.” However, it is to be understood that “concentration” as used herein, refers to both “analyte concentration” as that phrase would be ordinarily used and also to “activity” (in some cases “glucose activity”) as that phrase is described above.
Optical Glucose Sensor Configurations
With reference to
With reference to
With reference to
In certain embodiments, as illustrated in
In certain embodiments, the rod 140 is attached to the optical fiber 130 and/or atraumatic tip 134 by heating and expanding the optical fiber 130 and atraumatic tip 134 and embedding the rod 140 there between. In certain embodiments, the optical fiber 130 is heated to between about 100° C. and about 160° C., more preferably between about 110° C. and about 140° C. In other embodiments, the optical fiber 130 is first heated and then cooled one or more times. In certain embodiments, the rod 140 is attached to the optical fiber 130 and/or the atraumatic tip 134 by applying an adhesive. In preferred embodiments, the adhesive is biocompatible, such as for example, cyanoacrylates, epoxies, light cure adhesives, silicones, and urethanes. In certain embodiments, after applying the adhesive and joining the rod 140 with the optical fiber 130 and atraumatic tip 134, the adhesive is cured at room temperature, by heating, or by applying UV/visible light. In certain embodiments, the time to fix the rod 140 to the optical fiber 130 and/or atraumatic tip 134 can vary from about 5 seconds to about 60 seconds, from about 15 minutes to about 5 hours, from about 60 seconds to about 10 minutes, or up to about 24 hours.
In some embodiments, the proximal surface of the rod 144 is reflective so that a portion of the excitation light signal (or reference light signal) is reflected proximally down the optical fiber 130 to a detector (not shown). The term rod is used herein to refer to any elongate structural member, regardless of its geometry, configured to connect the atraumatic tip portion to the optical fiber. The rod may be centered coaxially (as illustrated) or off-centered with regard to the cross-section of the fiber and atraumatic tip portion. In some embodiments, there may be more than one rod extending between the fiber and the atraumatic tip portion. Where more than one rod is employed, the rods may be arranged symmetrically or asymmetrically with respect to the cross-section of the fiber and atraumatic tip portion.
In certain embodiments, as illustrated in
The hydrogel and glucose-sensing chemical indicator system is disposed within the cavity 116. In preferred embodiments, the hydrogel/chemical indicator system filled cavity 116 is covered by a selectively permeable membrane 142 that allows passage of glucose into and out of the hydrogel/chemical indicator system. Although these embodiments are described using a glucose sensor 117, it should be understood by a person of ordinary skill in the art that the sensor 117 can be modified to measure other analytes by changing, for example, the sensing chemistry, and if necessary, the selectively permeable membrane 142.
In certain embodiments, the selectively permeable membrane 142 is attached to the optical fiber 130 and the atraumatic tip 134 by means of an adhesive. In preferred embodiments, the adhesive is biocompatible, such as for example, cyanoacrylates, epoxies, light cure adhesives, silicones, and urethanes. In certain embodiments, after applying the adhesive and attaching the selectively permeable membrane 142 to the optical fiber 130 and atraumatic tip 134, the adhesive is cured at room temperature, by heating, or by applying UV/visible light. In certain embodiments, the time to adhere the selectively permeable membrane 142 to the optical fiber 130 and/or atraumatic tip 134 can vary from about 5 seconds to about 60 seconds, from about 15 minutes to about 5 hours, from about 60 seconds to about 10 minutes, or up to about 24 hours. In other embodiments, the selectively permeable membrane 142 is pre-fabricated as a sleeve. The sleeve may be slid into place and sealed using an adhesive and/or heated to form-fit the glucose sensor 117. In certain embodiments, the selectively permeable membrane 142 surrounds the entire circumference of the glucose sensor 117. In other embodiments, the selectively permeable membrane 142 covers a window 180 or opening in the glucose sensor 117 exposing the void or cavity 116 to analytes in the blood stream.
In some embodiments, as illustrated in
In some embodiments, the sensor 117, including the selectively permeable membrane 142, has a smooth surface. The smooth surface can be made for example by the method disclosed in co-pending U.S. patent application Ser. No. 12/026,396 (published as 2008/0187655). In summary, one preferred embodiment of the method comprises filling the cavity 116 with a solution comprising a monomer, crosslinker and an initiator, such as a thermal initiator. After the sensor 117 has been filled, the sensor 117 is dipped into liquid wax, which is allowed to harden around the sensor 117 and selectively permeable membrane 142.
The liquid wax has a melting point that is greater than the thermal initiation temperature. Therefore, in order to reduce the likelihood of initiation during the wax dipping and coating step, the filled sensor 117 can be chilled before the wax dipping and coating step. After the sensor 117 has been coated with wax, the solution in the cavity 116 can be deoxygenated by placing the sensor 117 in a water bath while bubbling an inert gas, such as nitrogen, in the bath.
After deoxygenation, polymerization can be initiated by heating the sensor 117 to a temperature above the thermal initiation temperature, but below the melting point of the wax. Once the solution is substantially polymerized into the hydrogel, the wax can be removed from the sensor by use of a solvent, such as hexane, leaving a sensor 117 with a smooth surface.
In some embodiments, as illustrated in
In some embodiments, the rod 140 has a proximal portion that is connected to the distal portion of the optical fiber 130 and a distal portion that is connected to the proximal portion of the atraumatic tip portion 134. The rod 140 can be made of a metal, metal alloy, plastic, polymer, ceramic, composite material or any other material with suitable mechanical properties for connecting the atraumatic tip portion 134 with the distal portion of the optical fiber 130. For example, the rod 140 can be made of stainless steel, titanium or Nitinol. The rod 140 can be cylindrical or noncylindrical, such as a bar with a square, rectangular, oval or oblong cross-section. In some embodiments, the diameter of the rod 140 is generally between about 0.001 to 0.010 inches. In other embodiments, the diameter of the rod 140 is generally between about 0.004 to 0.008 inches. In other embodiments, the diameter of the rod 140 is about 0.001 inches, about 0.002 inches or 0.004 inches. In some embodiments, the diameter of the rod 140 may be less than about 0.001 inches. In some embodiments, the diameter of the rod 140 may be greater than about 0.010 inches. In some embodiments, the length of the rod 140 is generally less than about 0.005 inches. In some embodiments, the length of the rod 140 is between about 0.005 to 0.040 inches. In other embodiments, the length of the rod 140 is generally between about 0.020 to 0.040 inches. In other embodiments, the length of the rod 140 is generally about 0.015 inches. In some embodiments, the length of the rod 140 is generally greater than about 0.005 inches.
The rod 140 adds mechanical stability to the distal portion of the sensor 117. In some embodiments, the rod 140 also adds flexibility to the distal portion of the sensor 117, allowing the atraumatic tip portion 134 to flex back and forth relative to the orientation of the optical fiber 130. The flexibility of the rod 140, and thus the degree which the atraumatic tip portion 134 can flex, can be increased or decreased by decreasing or increasing the diameter of the rod 140. In addition, the flexibility of the rod 140 can be altered by making the rod 140 from a stiff or flexible material.
In some embodiments as illustrated in
With regard to
In some embodiments, as shown in
In some embodiments, as illustrated in
In some embodiments, the diameter of the optical fiber 130 may be smaller than the diameter of the interior of the cage 195, allowing the optical fiber 130 to fit within the interior of the cage 195 and abut the void or cavity 116. For example, the diameter of the optical fiber 130 may be between about 0.005 inches and about 0.020 inches, between about 0.008 inches and about 0.014 inches, or between about 0.010 inches and about 0.012 inches. The diameter of the interior of the cage 195 may be about 0.001 inches larger.
In certain embodiments, the cage 195 has a window or opening 180, covered by a selectively permeable membrane 142 (not shown), which allows for at least the transmission of analytes, such a glucose, into the void or cavity 116. In certain preferred embodiments, the void or cavity 116 is filled with a hydrogel/chemical indicator system. A rod 140 may be positioned within the glucose sensor 117 having a reference material 190. As discussed above, the reference material 190 may be a minor for reflecting excitation light from the optical fiber 130 back to a detector (not shown) or a glucose-insensitive fluorescent dye for emitting a glucose-insensitive reference signal back to a detector (not shown). The combination of the cage 195 and the rod 140 may provide a sufficiently rigid structure such that the excitation light which enters the void or cavity 116 remains separate from the light that enters the reference material 190.
In some embodiments, as illustrated in
In
In
In certain embodiments, as illustrated in
A person skilled in the art would readily understand that the above described embodiments, or components of the above described embodiments, may be combined within the scope of the present invention. For example, a glucose sensor may contain one or more structural elements, such as a cage, a hypotube, and/or a rod within the scope of the present invention. In addition, a glucose sensor may contain one or more reference materials, functioning as a reflective surface and/or as a separate dye indicator system, in different locations and configurations within the scope of the present invention.
In some embodiments (see e.g.,
In some embodiments, the glucose sensor 117 includes a temperature sensor or probe 146, such as thermocouple or thermistor (See e.g.,
In certain embodiments, the temperature sensor can be a thermistor (as described above with regard to
Devices such as thermistors, platinum RTDs, and other RTDs generally require one or more conductors, such as wires, to conduct the output of the sensor to a receiving unit which converts the output to a temperature signal. The conductors can be bundled with the optical fiber of fluorescence-based glucose sensors, such as those discussed above, or they can be routed separately. In one embodiment, the temperature sensor is placed inside the body, and the receiver is placed outside the body. In another embodiment, the temperature sensor is placed inside the body, and a transmitter, signal processor, etc. is also placed inside the body and is connected to or is a part of the temperature sensor. In preferred embodiments, the temperature sensing element is located at or near the glucose sensing moiety.
In another embodiment, a fluorescence-based temperature sensing technique can be used. Fluorescence-based temperature sensing techniques include those based on fluorescence decay, such as where an excitation light is provided to a phosphor, the excitation light is stopped, and the fluorescence is monitored versus time, with the rate of decrease in fluorescence being related to the temperature of the phosphor. Various techniques, can also include phase measurement and phase angle analysis.
Methods for performing fluorescence-based temperature measurement have been described. See for example, LumaSense Technologies, Inc. (Santa Clara, Calif.), “Fluoroptic Temperature Monitoring,” http://www.lumasenseinc.com/technology/fluoroptic_thermometry.html. Fluorescent materials that can be used in fluorescence-based temperature measurement are known to, or readily identified by those having skill in the art.
In some embodiments, the fluorescent material can be surrounded by material which prevents or inhibits chemical interaction between the fluorescent material and blood components. Suitable materials include glass (for example, borosilicate, lime-soda, or other types including those used for fiberoptic cables), polymers (for example, Teflon, fluoropolymers, silicone, latex, polyolefins, polyisoprene, and other rigid and nonrigid polymeric materials), metals (for example, 300 series stainless steel, 400 series stainless steel, nickel, nickel alloys, chromium steels, zirconium and its alloys, titanium and its alloys, as well as other corrosion resistant metals and alloys including exotic metals and alloys), ceramics (for example, ceramic materials related to aluminum oxide, silica and oxide, zirconium, carbides, etc.), and combinations of these.
In some embodiments, the temperature sensor can be positioned within the glucose sensor, or near it. While in one preferred embodiment, the temperature sensor can be positioned as close as possible to (e.g., within) the glucose-sensing chemical indicator system of the glucose sensor, positions some distance away can also be successfully utilized, including those locations where the temperature measured provides an indication of the temperature at the glucose-sensing site(s) within an acceptable error for the use for which the temperature measurement is being made.
In some embodiments, the temperature sensor and/or the leads to the sensor can be isolated from the physiological environment, such as by coating, covering, or encasing the various parts with a material that prevents or inhibits chemical or physical interaction between the temperature sensor and/or its leads and blood components. Chemical interactions that are preferably avoided include corrosion, leaching of chemical species, generation of additional signals (e.g. optical, electrical, etc.) and take-up by the body of materials present in the sensor or leads, whether present from manufacture, corrosion or other means, such as compounds, metals, or ions causing a physiological response in some patients including copper, silver, organic compounds, organometallic compounds, etc.
Physical interactions can include breakage and physical separation (e.g. disconnection and potential loss), signal leakage (e.g. optical; electrical, etc.), signal degradation (including resistance, stray signal detection, noise, capacitance, electrochemical effects, induced voltages, ground loops, etc.). Suitable materials include glass (e.g., borosilicate, lime-soda, as well as other types of glass, such as those used in production of optic fibers), polymers (e.g., Teflon, fluoropolymers, silicone, latex, polyolefins, polyisoprene, acrylics, polycarbonates, and other rigid and nonrigid polymeric materials), metals (e.g., 300 series stainless steel, 400 series stainless steel, nickel, nickel alloys, chromium steels, zirconium and its alloys, titanium and its alloys, as well as other corrosion resistant metals and alloys including exotic metals and alloys), ceramics (e.g., ceramic materials related to aluminum oxide, silica and oxide, zirconium, carbides, etc.), and combinations of these.
Suitable methods for applying for isolating material to the temperature sensor or leads can include any appropriate method, including casting, painting, dipping, gluing, reacting, drawing, depositing, mechanically adhering, encapsulating, etc.
In some embodiments, suitable sizes for temperature sensors that will be incorporated into the glucose sensor include those temperature sensing elements resulting in an overall glucose sensor of between about 0.005 inches and 0.020 inches.
After the excitation light passes through the glucose fiber 1310 and the reference fiber 1320, the glucose sensing hydrogel 1330 and the reference material 1340 emit fluorescent signals back to two separate detectors, a glucose signal detector 1350 and a reference signal detector 1360, for ratiometric processing. The benefit of the dual fiber configuration is that both fibers 1310, 1320 experience the same external pressure, bending, temperature, and other external factors. In addition, both fibers 1310, 1320 contain substantially the same material in the glucose sensing hydrogel 1330 and reference material 1340. As a result, the ratio of the intensities between the two fibers 1310, 1320, as measured by the detectors 1350, 1360, produce a calibrated glucose signal that removes, inter alia, the effect of the fluctuations in the LED output or altered transmission along the optical fiber, and thereby increase the accuracy in the measurement of the glucose concentration.
With reference to
In certain preferred embodiments, the fluorophore dye may be selected such that it exists in distinguishable acid and base conformations, each of which emit at a distinct wavelength, and wherein the relative proportion of acid and base forms depend on the pH. The ratio of intensities of the acid and base emissions can be used to determine the pH of the blood (as detailed in US Patent Publication No. 2008/0188722; incorporated herein in its entirety by reference thereto). The ratio of the acid or base emission intensity over the excitation light can be used to determine the level of glucose in the blood. Of course in a variation to this single exciter-dual emitter fluorophore system, one could employ a single exciter-single emitter for detection of glucose concentration without simultaneous ratiometric determination of pH. Indeed, a great variety of design options are available (see e.g., US Patent Publication Nos. 2008/0188725 and 2008/0188722), wherein the chemical indicator and optical systems may be selected based on the preferred use.
Glucose-Sensing Chemical Indicator Systems
In certain embodiments, the hydrogels are associated with a plurality of fluorophore systems. In certain embodiments, the fluorophore systems comprise a quencher with a glucose receptor site. In certain embodiments, when there is no glucose present to bind with the glucose receptor, the quencher prevents the fluorophore system from emitting light when the dye is excited by an excitation light. In certain embodiments, when there is glucose present to bind with the glucose receptor, the quencher allows the fluorophore system to emit light when the dye is excited by an excitation light.
In certain embodiments, the emission produced by the fluorophore system may vary with the pH (as well as the temperature) of the solution (for example, blood), such that different excitation wavelengths (one exciting the acid form of the fluorophore and the other the base form of the fluorophore) produce different emissions signals. In preferred embodiments, the ratio of the emission signal from the acid form of the fluorophore over the emission signal from the base form of the fluorophore is related to the pH level of the blood. In certain embodiments, an interference filter is employed to ensure that the two excitation lights are exciting only one form (the acid form or the base form) of the fluorophore. Chemical indicator systems, hardware configurations and methods for determining both pH and glucose based on ratiometric determination are described in detail in co-pending U.S. application Ser. Nos. 11/671,880 (published as 2008/0188722) and 12/027,158 (published as 2008/0188725); incorporated herein in their entirety by reference thereto.
The indicator system (also referred to herein as a fluorophore system) can comprise a fluorophore operably coupled to a quencher. In certain embodiments, the fluorophore system comprises a polymer matrix comprising a fluorophore susceptible to quenching by a viologen, a viologen quencher with quenching efficacy dependent on glucose concentration, and a glucose permeable polymer, wherein said matrix is in contact with blood in vivo. Preferably the fluorophore is a fluorescent organic dye, the quencher is a boronic acid functionalized viologen, and the matrix is a hydrogel.
“Fluorophore” refers to a substance that when illuminated by light at a particular wavelength emits light at a longer wavelength; i.e. it fluoresces. Fluorophores include but are not limited to organic dyes, organometallic compounds, metal chelates, fluorescent conjugated polymers, quantum dots or nanoparticles and combinations of the above. Fluorophores may be discrete moieties or substituents attached to a polymer.
Fluorophores that may be used in preferred embodiments are capable of being excited by light of wavelength at or greater than about 400 nm, with a Stokes shift large enough that the excitation and emission wavelengths are separable by at least 10 nm. In some embodiments, the separation between the excitation and emission wavelengths may be equal to or greater than about 30 nm. These fluorophores are preferably susceptible to quenching by electron acceptor molecules, such as viologens, and are resistant to photo-bleaching. They are also preferably stable against photo-oxidation, hydrolysis and biodegradation.
In some embodiments, the fluorophore may be a discrete compound.
In some embodiments, the fluorophore may be a pendant group or a chain unit in a water-soluble or water-dispersible polymer having molecular weight of about 10,000 daltons or greater, forming a dye-polymer unit. In one embodiment, such dye-polymer unit may also be non-covalently associated with a water-insoluble polymer matrix M1 and is physically immobilized within the polymer matrix M1, wherein M1 is permeable to or in contact with an analyte solution. In another embodiment, the dye on the dye-polymer unit may be negatively charged, and the dye-polymer unit may be immobilized as a complex with a cationic water-soluble polymer, wherein said complex is permeable to or in contact with the analyte solution. In one embodiment, the dye may be one of the polymeric derivatives of hydroxypyrene trisulfonic acid. The polymeric dyes may be water-soluble, water-swellable or dispersible in water. In some embodiments, the polymeric dyes may also be cross-linked. In preferred embodiments, the dye has a negative charge.
In other embodiments, the dye molecule may be covalently bonded to the water-insoluble polymer matrix M1, wherein said M1 is permeable to or in contact with the analyte solution. The dye molecule bonded to M1 may form a structure M1-L1-Dye. L1 is a hydrolytically stable covalent linker that covalently connects the sensing moiety to the polymer or matrix. Examples of L1 include lower alkylene (e.g., C1-C8 alkylene), optionally terminated with or interrupted by one or more divalent connecting groups selected from sulfonamide (—SO2NH—), amide —(C═O)N—, ester —(C═O)—O—, ether. —O—, sulfide —S—, sulfone (—SO2—), phenylene —C6H4—, urethane —NH(C═O)—O—, urea —NH(C═O)NH—, thiourea —NH(C═S)—NH—, amide —(C═O)NH—, amine —NR— (where R is defined as alkyl having 1 to 6 carbon atoms) and the like, or a combination thereof. In one embodiment, the dye is bonded to a polymer matrix through the sulfonamide functional groups.
In one preferred embodiment, the fluorophore may be HPTS-CysMA (structure illustrated below); see U.S. Pat. No. 7,417,164, incorporated in its entirety herein by reference thereto.
Of course, in some embodiments, substitutions other than Cys-MA on the HPTS core are consistent with aspects of the present invention, as long as the substitutions are negatively charged and have a polymerizable group. Either L or D stereoisomers of cysteine may be used. In some embodiments, only one or two of the sulfonic acids may be substituted. Likewise, in variations to HPTS-CysMA shown above, other counterions besides NBu4+ may be used, including positively charged metals, e.g., Na+. In other variations, the sulfonic acid groups may be replaced with e.g., phosphoric, carboxylic, etc. functional groups.
Fluorescent dyes, including HPTS and its derivatives are known and many have been used in analyte detection. See e.g., U.S. Pat. Nos. 6,653,141, 6,627,177, 5,512,246, 5,137,833, 6,800,451, 6,794,195, 6,804,544, 6,002,954, 6,319,540, 6,766,183, 5,503,770, and 5,763,238; each of which is incorporated herein in its entirety by reference thereto.
In accordance with broad aspects of the present invention, the analyte binding moiety provides the at least dual functionality of being able to bind analyte and being able to modulate the apparent concentration of the fluorophore (e.g., detected as a change in emission signal intensity) in a manner related to the amount of analyte binding. In preferred embodiments, the analyte binding moiety is associated with a quencher. “Quencher” refers to a compound that reduces the emission of a fluorophore when in its presence. Quencher (Q) is selected from a discrete compound, a reactive intermediate which is convertible to a second discrete compound or to a polymerizable compound or Q is a pendant group or chain unit in a polymer prepared from said reactive intermediate or polymerizable compound, which polymer is water-soluble or dispersible or is an insoluble polymer, said polymer is optionally crosslinked.
In one example, the moiety that provides glucose recognition in the embodiments is an aromatic boronic acid. The boronic acid is covalently bonded to a conjugated nitrogen-containing heterocyclic aromatic bis-onium structure (e.g., a viologen). “Viologen” refers generally to compounds having the basic structure of a nitrogen containing conjugated N-substituted heterocyclic aromatic bis-onium salt, such as 2,2′-, 3,3′- or 4,4′-N,N′ bis-(benzyl) bipyridium dihalide (i.e., dichloride, bromide chloride), etc. Viologen also includes the substituted phenanthroline compounds. The boronic acid substituted quencher preferably has a pKa of between about 4 and 9, and reacts reversibly with glucose in aqueous media at a pH from about 6.8 to 7.8 to form boronate esters. The extent of reaction is related to glucose concentration in the medium. Formation of a boronate ester diminishes quenching of the fluorophore by the viologen resulting in an increase in fluorescence dependent on glucose concentration. A useful bis-onium salt is compatible with the analyte solution and capable of producing a detectable change in the fluorescent emission of the dye in the presence of the analyte to be detected.
Bis-onium salts in the embodiments of this invention are prepared from conjugated heterocyclic aromatic di-nitrogen compounds. The conjugated heterocyclic aromatic di-nitrogen compounds are selected from dipyridyls, dipyridyl ethylenes, dipyridyl phenylenes, phenanthrolines, and diazafluorenes, wherein the nitrogen atoms are in a different aromatic ring and are able to form an onium salt. It is understood that all isomers of said conjugated heterocyclic aromatic di-nitrogen compounds in which both nitrogens can be substituted are useful in this invention. In one embodiment, the quencher may be one of the bis-onium salts derived from 3,3′-dipyridyl, 4,4′-dipyridyl and 4,7-phenanthroline.
In some embodiments, the viologen-boronic acid adduct may be a discrete compound having a molecular weight of about 400 daltons or greater. In other embodiments, it may also be a pendant group or a chain unit of a water-soluble or water-dispersible polymer with a molecular weight greater than about 10,000 daltons. In one embodiment, the quencher-polymer unit may be non-covalently associated with a polymer matrix and is physically immobilized therein. In yet another embodiment, the quencher-polymer unit may be immobilized as a complex with a negatively charge water-soluble polymer.
In other embodiments, the viologen-boronic acid moiety may be a pendant group or a chain unit in a crosslinked, hydrophilic polymer or hydrogel sufficiently permeable to the analyte (e.g., glucose) to allow equilibrium to be established.
In other embodiments, the quencher may be covalently bonded to a second water-insoluble polymer matrix M2, which can be represented by the structure M2-L2-Q. L2 is a linker selected from the group consisting of a lower alkylene (e.g., C1-C8 alkylene), sulfonamide, amide, quaternary ammonium, pyridinium, ester, ether, sulfide, sulfone, phenylene, urea, thiourea, urethane, amine, and a combination thereof. The quencher may be linked to M2 at one or two sites in some embodiments.
In certain embodiments, at least one quencher precursor is used to attach the quenching moiety to at least one polymer. For example, aromatic groups may be used to functionalize a viologen with combinations of boronic acid groups and reactive groups. In certain embodiments, this process includes attaching an aromatic group to each of the two nitrogens in the dipyridyl core of the viologen. At least one boronic acid group, a reactive group, or a combination of the two are then attached to each aromatic group, such that the groups attached to each of the two nitrogens on the dipyridyl core of the viologen may either be the same or different. Certain combinations of the functionalized viologen quenching moiety are described as follows:
Preferred embodiments comprise two boronic acid moieties and one polymerizable group or coupling group wherein the aromatic group is a benzyl substituent bonded to the nitrogen and the boronic acid groups are attached to the benzyl ring and may be in the ortho- meta- or para-positions.
In one preferred embodiment, the quencher precursor (before incorporation into a hydrogel) may be 3,3′-oBBV (structure illustrated below); see U.S. Pat. No. 7,470,420, incorporated in its entirety herein by reference thereto.
The quencher precursor 3,3′-oBBV may be used with HPTS-CysMA to make hydrogels in accordance with preferred aspects of the invention.
Other indicator chemistries, such as those disclosed in U.S. Pat. No. 5,176,882 to Gray et al. and Pat. No. 5,137,833 to Russell, can also be used in accordance with embodiments of the present invention; both of which are incorporated herein in their entireties by reference thereto. In some embodiments, an indicator system may comprise an analyte binding protein operably coupled to a fluorophore, such as the indicator systems and glucose binding proteins disclosed in U.S. Pat. Nos. 6,197,534, 6,227,627, 6,521,447, 6,855,556, 7,064,103, 7,316,909, 7,326,538, 7,345,160, and 7,496,392, U.S. Patent Application Publication Nos. 2003/0232383, 2005/0059097, 2005/0282225, 2009/0104714, 2008/0311675, 2008/0261255, 2007/0136825, 2007/0207498, and 2009/0048430, and PCT International Publication Nos. WO 2009/021052, WO 2009/036070, WO 2009/021026, WO 2009/021039, WO 2003/060464, and WO 2008/072338 which are hereby incorporated by reference herein in their entireties.
For in vivo applications, the sensor is used in a moving stream of physiological fluid which contains one or more polyhydroxyl organic compounds or is implanted in tissue such as muscle which contains said compounds. Therefore, it is preferred that none of the sensing moieties escape from the sensor assembly. Thus, for use in vivo, the sensing components are preferably part of an organic polymer sensing assembly. Soluble dyes and quenchers can be confined by a selectively permeable membrane that allows passage of the analyte but blocks passage of the sensing moieties. This can be realized by using as sensing moieties soluble molecules that are substantially larger than the analyte molecules (molecular weight of at least twice that of the analyte or greater than 1000 preferably greater than 5000); and employing a selective semipermeable membrane such as a dialysis or an ultrafiltration membrane with a specific molecular weight cutoff between the two so that the sensing moieties are quantitatively retained.
Preferably the sensing moieties are immobilized in an insoluble polymer matrix, which is freely permeable to glucose. The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials. Alternatively, the matrix is coated with a second biocompatible polymer that is permeable to the analytes of interest.
The function of the polymer matrix is to hold together and immobilize the fluorophore and quencher moieties while at the same time allowing contact with the analyte, and binding of the analyte to the boronic acid. To achieve this effect, the matrix must be insoluble in the medium, and in close association with it by establishing a high surface area interface between matrix and analyte solution. For example, an ultra-thin film or microporous support matrix is used. Alternatively, the matrix is swellable in the analyte solution, e.g. a hydrogel matrix is used for aqueous systems. In some instances, the sensing polymers are bonded to a surface such as the surface of a light conduit, or impregnated in a microporous membrane. In all cases, the matrix must not interfere with transport of the analyte to the binding sites so that equilibrium can be established between the two phases. Techniques for preparing ultra-thin films, microporous polymers, microporous sol-gels, and hydrogels are established in the art. All useful matrices are defined as being analyte permeable.
Hydrogel polymers are used in some embodiments. The term, hydrogel, as used herein refers to a polymer that swells substantially, but does not dissolve in water. Such hydrogels may be linear, branched, or network polymers, or polyelectrolyte complexes, with the proviso that they contain no soluble or leachable fractions. Typically, hydrogel networks are prepared by a crosslinking step, which is performed on water-soluble polymers so that they swell but do not dissolve in aqueous media. Alternatively, the hydrogel polymers are prepared by copolymerizing a mixture of hydrophilic and crosslinking monomers to obtain a water swellable network polymer. Such polymers are formed either by addition or condensation polymerization, or by combination process. In these cases, the sensing moieties are incorporated into the polymer by copolymerization using monomeric derivatives in combination with network-forming monomers. Alternatively, reactive moieties are coupled to an already prepared matrix using a post polymerization reaction. Said sensing moieties are units in the polymer chain or pendant groups attached to the chain.
The hydrogels useful in this invention are also monolithic polymers, such as a single network to which both dye and quencher are covalently bonded, or multi-component hydrogels. Multi-component hydrogels include interpenetrating networks, polyelectrolyte complexes, and various other blends of two or more polymers to obtain a water swellable composite, which includes dispersions of a second polymer in a hydrogel matrix and alternating microlayer assemblies.
Monolithic hydrogels are typically formed by free radical copolymerization of a mixture of hydrophilic monomers, including but not limited to HEMA, PEGMA, methacrylic acid, hydroxyethyl acrylate, N-vinyl pyrrolidone, acrylamide, N,N′-dimethyl acrylamide, and the like; ionic monomers include methacryloylaminopropyl trimethylammonium chloride, diallyl dimethyl ammonium. chloride, vinyl benzyl trimethyl ammonium chloride, sodium sulfopropyl methacrylate, and the like; crosslinkers include ethylene dimethacrylate, PEGDMA, trimethylolpropane triacrylate, and the like. The ratios of monomers are chosen to optimize network properties including permeability, swelling index, and gel strength using principles well established in the art. In one embodiment, the dye moiety is derived from an ethylenically unsaturated derivative of a dye molecule, such as 8-acetoxypyrene-1,3,6-N,N′,N″-tris(methacrylamidopropylsulfonamide), the quencher moiety is derived from an ethylenically unsaturated viologen such as 4-N-(benzyl-3-boronic acid)-4′-N′-(benzyl-4-ethenyl)-dipyridinium dihalide (m-SBBV) and the matrix is made from HEMA and PEGDMA. The concentration of dye is chosen to optimize emission intensity. The ratio of quencher to dye is adjusted to provide sufficient quenching to produce the desired measurable signal.
In some embodiments, a monolithic hydrogel is formed by a condensation polymerization. For example, acetoxy pyrene trisulfonyl chloride is reacted with an excess of PEG diamine to obtain a tris-(amino PEG) adduct dissolved in the unreacted diamine. A solution of excess trimesoyl chloride and an acid acceptor is reacted with 4-N-(benzyl-3-boronic acid)-4′-N′-(2 hydroxyethyl) bipyridinium dihalide to obtain an acid chloride functional ester of the viologen. The two reactive mixtures are brought into contact with each other and allowed to react to form the hydrogel, e.g. by casting a thin film of one mixture and dipping it into the other.
In other embodiments, multi-component hydrogels wherein the dye is incorporated in one component and the quencher in another are preferred for making the sensor of this invention. Further, these systems are optionally molecularly imprinted to enhance interaction between components and to provide selectivity for glucose over other polyhydroxy analytes. Preferably, the multicomponent system is an interpenetrating polymer network (IPN) or a semi-interpenetrating polymer network (semi-IPN).
The IPN polymers are typically made by sequential polymerization. First, a network comprising the quencher is formed. The network is then swollen with a mixture of monomers including the dye monomer and a second polymerization is carried out to obtain the IPN hydrogel.
The semi-IPN hydrogel is formed by dissolving a soluble polymer containing dye moieties in a mixture of monomers including a quencher monomer and through complex formation with the fluorophore. In some embodiments, the sensing moieties are immobilized by an insoluble polymer matrix which is freely permeable to polyhydroxyl compounds. Additional details on hydrogel systems have been disclosed in US Patent Publications Nos. US2004/0028612, and 2006/0083688 which are hereby incorporated by reference in their entireties.
The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials. Alternatively, the matrix is coated with a second biocompatible polymer that is permeable to the analytes of interest. The function of the polymer matrix is to hold together and immobilize the fluorescent dye and quencher moieties while at the same time allowing contact with the analytes (e.g., polyhydroxyl compounds, H+ and OH−), and binding of the polyhydroxyl compounds to the boronic acid. Therefore, the matrix is insoluble in the medium and in close association with it by establishing a high surface area interface between matrix and analyte solution. The matrix also does not interfere with transport of the analyte to the binding sites so that equilibrium can be established between the two phases. In one embodiment, an ultra-thin film or microporous support matrix may be used. In another embodiment, the matrix that is swellable in the analyte solution (e.g. a hydrogel matrix) can be used for aqueous systems. In some embodiments, the sensing polymers are bonded to a surface such as the surface of a light conduit, or impregnated in a microporous membrane. Techniques for preparing ultra-thin films, microporous polymers, microporous sol-gels, and hydrogels have been established in the prior art.
In one preferred embodiment, the boronic acid substituted viologen may be covalently bonded to a fluorescent dye. The adduct may be a polymerizable compound or a unit in a polymer. One such adduct for example may be prepared by first forming an unsymmetrical viologen from 4,4′-dipyridyl by attaching a benzyl-3-boronic acid group to one nitrogen and an aminoethyl group to the other nitrogen atom. The viologen is condensed sequentially first with 8-acetoxy-pyrene-1,3,6-trisulfonyl chloride in a 1:1 mole ratio followed by reaction with excess PEG diamine to obtain a prepolymer mixture. An acid acceptor is included in both steps to scavenge the byproduct acid. The prepolymer mixture is crosslinked by reaction with a polyisocyanate to obtain a hydrogel. The product is treated with base to remove the acetoxy blocking group. Incomplete reaction products and unreacted starting materials are leached out of the hydrogel by exhaustive extraction with deionized water before further use. The product is responsive to glucose when used as the sensing component as described herein.
Alternatively, such adducts are ethylenically unsaturated monomer derivatives. For example, dimethyl bis-bromomethyl benzene boronate is reacted with excess 4,4′-dipyridyl to form a half viologen adduct. After removing the excess dipyridyl, the adduct is further reacted with an excess of bromoethylamine hydrochloride to form the bis-viologen adduct. This adduct is coupled to a pyranine dye by reaction with the 8-acetoxypyrene-tris sulfonyl chloride in a 1:1 mole ratio in the presence of an acid acceptor followed by reaction with excess aminopropylmethacrylamide. Finally, any residual amino groups may be reacted with methacrylol chloride. After purification, the dye/viologen monomer may be copolymerized with HEMA and PEGDMA to obtain a hydrogel.
To a solution of HPTS-CysMA (1×10−5 M in pH 7.4 PBS) was added increasing amounts of 3,3′-oBBV (30 mM in MeOH) and the fluorescence emission measured after each addition.
HPTS-CysMA (1×10−5 M) and 3,3′-oBBV (3×10−3 M) were titrated with a stock solution of glucose (31250 mg/dL) in pH 7.4 PBS and the fluorescence emission measured after each addition of glucose. The relative change upon addition of glucose is given in
HPTS-CysMA (2 mg), 3,3′-oBBV (15 mg), N,N′-dimethylacrylamide (400 mg), N,N′-methylenebisacrylamide (8 mg), HCl (10 μL of 1 M solution), and VA-044 (1 mg) were dissolved in water and diluted to 1 mL in a volumetric flask. The solution was freeze-pump-thawed (3×), injected into a mold containing a 0.005″ polyimide spacer and polymerized at 55° C. for 16 h. The resultant film was placed in pH 7.4 phosphate buffer and was tested in a flow cell configuration with increasing amounts of glucose (0, 50, 100, 200, 400 mg/dL). The relative fluorescence change upon addition of glucose is given in
Although the foregoing invention has been described in terms of certain embodiments and examples, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. Moreover, the described embodiments have been presented by way of example only, and are not intended to limit the scope of the inventions. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms without departing from the spirit thereof. Accordingly, other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein. Thus, the present invention is not intended to be limited by the example or preferred embodiments. The accompanying claims provide exemplary claims and their equivalents are intended to cover forms or modifications as would fall within the scope and spirit of the inventions.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1120700 | Ehrlich | Dec 1914 | A |
| 1334901 | Higdon | Mar 1920 | A |
| 2112244 | Jurist | Mar 1938 | A |
| 2274551 | Kenyon et al. | Feb 1942 | A |
| 2496151 | Dawson et al. | Jan 1950 | A |
| 2812524 | Pruitt | Nov 1957 | A |
| 3011293 | Rado | Dec 1961 | A |
| 3302219 | Harris | Feb 1967 | A |
| 3488098 | Sobczak | Jan 1970 | A |
| 3659586 | Johns et al. | May 1972 | A |
| 3795239 | Eberhard et al. | Mar 1974 | A |
| 3827089 | Grow | Aug 1974 | A |
| 3865548 | Padawer | Feb 1975 | A |
| 3874010 | Geary | Apr 1975 | A |
| 3884225 | Witter | May 1975 | A |
| 3895403 | Davis | Jul 1975 | A |
| 3905888 | Mindt et al. | Sep 1975 | A |
| 3909504 | Browne | Sep 1975 | A |
| 3924281 | Gibbs | Dec 1975 | A |
| 3930580 | Bazell et al. | Jan 1976 | A |
| 3996345 | Ullman | Dec 1976 | A |
| 4003707 | Lübbers et al. | Jan 1977 | A |
| 4041932 | Fostick | Aug 1977 | A |
| 4094578 | DiVita et al. | Jun 1978 | A |
| 4180879 | Mann | Jan 1980 | A |
| 4197853 | Parker | Apr 1980 | A |
| 4200110 | Peterson et al. | Apr 1980 | A |
| 4245645 | Arseneault et al. | Jan 1981 | A |
| 4269605 | Dean et al. | May 1981 | A |
| 4306562 | Osborne | Dec 1981 | A |
| 4307933 | Palmer et al. | Dec 1981 | A |
| 4308254 | Tayot et al. | Dec 1981 | A |
| 4344438 | Schultz | Aug 1982 | A |
| 4345606 | Littleford | Aug 1982 | A |
| 4358851 | Scilfres et al. | Nov 1982 | A |
| 4361918 | Roisseth | Dec 1982 | A |
| 4371374 | Cerami et al. | Feb 1983 | A |
| 4459712 | Pathan | Jul 1984 | A |
| 4465335 | Eppes | Aug 1984 | A |
| 4469357 | Martin | Sep 1984 | A |
| 4474431 | Bricheno | Oct 1984 | A |
| 4476870 | Peterson et al. | Oct 1984 | A |
| 4490867 | Gabrielsson | Jan 1985 | A |
| 4495293 | Shaffar | Jan 1985 | A |
| 4502169 | Persson | Mar 1985 | A |
| RE31879 | Lübbers et al. | May 1985 | E |
| 4528616 | Koppensteiner | Jul 1985 | A |
| 4548907 | Seitz et al. | Oct 1985 | A |
| 4557900 | Heitzmann | Dec 1985 | A |
| 4560248 | Cramp et al. | Dec 1985 | A |
| 4568444 | Nakamura et al. | Feb 1986 | A |
| 4600310 | Cramp et al. | Jul 1986 | A |
| 4621049 | Wang | Nov 1986 | A |
| 4629451 | Winters et al. | Dec 1986 | A |
| 4636144 | Abe et al. | Jan 1987 | A |
| 4649271 | Hök et al. | Mar 1987 | A |
| 4650472 | Bates | Mar 1987 | A |
| 4654031 | Lentz | Mar 1987 | A |
| 4659817 | Gallop et al. | Apr 1987 | A |
| 4675925 | Littleton | Jun 1987 | A |
| 4684538 | Klemarczyk | Aug 1987 | A |
| RE32514 | Steklenski | Oct 1987 | E |
| 4703756 | Gough et al. | Nov 1987 | A |
| 4707056 | Bittner | Nov 1987 | A |
| 4710623 | Lipson et al. | Dec 1987 | A |
| 4727730 | Boiarski et al. | Mar 1988 | A |
| 4737153 | Shimamura et al. | Apr 1988 | A |
| 4744618 | Mahlein | May 1988 | A |
| 4746751 | Oviatt | May 1988 | A |
| 4750795 | Blotekjaer | Jun 1988 | A |
| 4751918 | Bernard et al. | Jun 1988 | A |
| 4754538 | Stewart, Jr. et al. | Jul 1988 | A |
| 4776047 | DiMatteo | Oct 1988 | A |
| 4785814 | Kane | Nov 1988 | A |
| 4794619 | Tregay | Dec 1988 | A |
| 4796633 | Zwirkoski | Jan 1989 | A |
| 4798738 | Yafuso et al. | Jan 1989 | A |
| 4801187 | Elbert et al. | Jan 1989 | A |
| 4803049 | Hirschfeld et al. | Feb 1989 | A |
| 4816130 | Karakelle et al. | Mar 1989 | A |
| 4820636 | Hill et al. | Apr 1989 | A |
| 4821738 | Iwasaki et al. | Apr 1989 | A |
| 4822127 | Kamiya et al. | Apr 1989 | A |
| 4833091 | Leader et al. | May 1989 | A |
| 4838269 | Robinson et al. | Jun 1989 | A |
| 4846543 | Kapany et al. | Jul 1989 | A |
| 4851195 | Matthews et al. | Jul 1989 | A |
| 4854321 | Boiarski | Aug 1989 | A |
| 4861728 | Wagner | Aug 1989 | A |
| 4872226 | Lonardo | Oct 1989 | A |
| 4872759 | Stich-Baumeister | Oct 1989 | A |
| 4886338 | Yafuso et al. | Dec 1989 | A |
| 4889407 | Markle et al. | Dec 1989 | A |
| 4903707 | Knute et al. | Feb 1990 | A |
| 4906232 | Reynolds | Mar 1990 | A |
| 4923273 | Taylor | May 1990 | A |
| 4927222 | Kamiya et al. | May 1990 | A |
| 4937901 | Brennan | Jul 1990 | A |
| 4939801 | Schaal et al. | Jul 1990 | A |
| 4941308 | Grabenkort et al. | Jul 1990 | A |
| 4943364 | Koch et al. | Jul 1990 | A |
| 4946038 | Eaton | Aug 1990 | A |
| 4955862 | Sepetka | Sep 1990 | A |
| 4960412 | Fink | Oct 1990 | A |
| 4966597 | Cosman | Oct 1990 | A |
| 5000901 | Iyer et al. | Mar 1991 | A |
| 5005576 | Günther | Apr 1991 | A |
| 5007704 | McCartney | Apr 1991 | A |
| 5012809 | Shulze | May 1991 | A |
| 5018225 | Fergni et al. | May 1991 | A |
| 5030420 | Bacon | Jul 1991 | A |
| 5047208 | Schweitzer et al. | Sep 1991 | A |
| 5047627 | Yim et al. | Sep 1991 | A |
| 5054497 | Kapp et al. | Oct 1991 | A |
| 5068931 | Smith | Dec 1991 | A |
| 5069674 | Fearnot et al. | Dec 1991 | A |
| 5082112 | Dunklee | Jan 1992 | A |
| 5093266 | Leader et al. | Mar 1992 | A |
| 5098618 | Zelez | Mar 1992 | A |
| 5104388 | Quackenbush | Apr 1992 | A |
| 5108502 | Pawlowski et al. | Apr 1992 | A |
| 5109452 | Selvin et al. | Apr 1992 | A |
| 5114676 | Leiner et al. | May 1992 | A |
| 5119463 | Vurek | Jun 1992 | A |
| 5137833 | Russell | Aug 1992 | A |
| 5141497 | Erskine | Aug 1992 | A |
| 5162130 | McLaughlin | Nov 1992 | A |
| 5166990 | Riccitelli et al. | Nov 1992 | A |
| 5167715 | Kalafala et al. | Dec 1992 | A |
| 5168587 | Shutes | Dec 1992 | A |
| 5175016 | Yafuso et al. | Dec 1992 | A |
| 5176882 | Gray et al. | Jan 1993 | A |
| 5178267 | Grabenkort et al. | Jan 1993 | A |
| 5180376 | Fischell | Jan 1993 | A |
| 5182353 | Hui et al. | Jan 1993 | A |
| 5185263 | Kroneis et al. | Feb 1993 | A |
| 5217691 | Greene et al. | Jun 1993 | A |
| 5230031 | Markle | Jul 1993 | A |
| 5246109 | Markle et al. | Sep 1993 | A |
| 5246441 | Ross et al. | Sep 1993 | A |
| 5257338 | Markle | Oct 1993 | A |
| 5262037 | Markle et al. | Nov 1993 | A |
| 5279596 | Castaneda et al. | Jan 1994 | A |
| 5280130 | Markle et al. | Jan 1994 | A |
| 5280548 | Atwater et al. | Jan 1994 | A |
| 5286294 | Ebi et al. | Feb 1994 | A |
| 5290266 | Rohling et al. | Mar 1994 | A |
| 5302731 | Pitner et al. | Apr 1994 | A |
| 5305740 | Kolobow | Apr 1994 | A |
| 5310471 | Markle et al. | May 1994 | A |
| 5312344 | Grinfeld | May 1994 | A |
| 5322513 | Walker | Jun 1994 | A |
| 5334157 | Klein et al. | Aug 1994 | A |
| 5354448 | Markle et al. | Oct 1994 | A |
| 5357732 | Markle et al. | Oct 1994 | A |
| 5361758 | Hall et al. | Nov 1994 | A |
| 5380304 | Parker | Jan 1995 | A |
| 5389217 | Singer | Feb 1995 | A |
| 5409469 | Schaerf | Apr 1995 | A |
| 5503770 | James et al. | Apr 1996 | A |
| 5511408 | Yoshioka et al. | Apr 1996 | A |
| 5511547 | Markle et al. | Apr 1996 | A |
| 5512246 | Russell et al. | Apr 1996 | A |
| 5545179 | Williamson, IV | Aug 1996 | A |
| 5558714 | Watanabe et al. | Sep 1996 | A |
| 5569186 | Lord et al. | Oct 1996 | A |
| 5596988 | Markle et al. | Jan 1997 | A |
| 5618587 | Markle et al. | Apr 1997 | A |
| 5622259 | Church | Apr 1997 | A |
| 5634911 | Hermann et al. | Jun 1997 | A |
| 5643212 | Coutre et al. | Jul 1997 | A |
| 5658264 | Samson | Aug 1997 | A |
| 5669920 | Conley et al. | Sep 1997 | A |
| 5676784 | McGaffigan | Oct 1997 | A |
| D388418 | Polson et al. | Dec 1997 | S |
| 5700253 | Parker | Dec 1997 | A |
| 5702373 | Samson | Dec 1997 | A |
| 5747666 | Willis | May 1998 | A |
| 5755704 | Lunn | May 1998 | A |
| 5763238 | James et al. | Jun 1998 | A |
| 5797876 | Spears et al. | Aug 1998 | A |
| 5810985 | Bao et al. | Sep 1998 | A |
| 5827242 | Follmer et al. | Oct 1998 | A |
| 5891100 | Fleckenstein | Apr 1999 | A |
| 5891114 | Chien et al. | Apr 1999 | A |
| 5922612 | Alder et al. | Jul 1999 | A |
| 5947940 | Beisel | Sep 1999 | A |
| 5951929 | Wilson | Sep 1999 | A |
| 5954651 | Berg et al. | Sep 1999 | A |
| 6002954 | Van Antwerp et al. | Dec 1999 | A |
| 6011984 | Van Antwerp et al. | Jan 2000 | A |
| 6019736 | Avellanet et al. | Feb 2000 | A |
| 6152933 | Werp et al. | Nov 2000 | A |
| 6156010 | Kuracina et al. | Dec 2000 | A |
| 6187130 | Berard et al. | Feb 2001 | B1 |
| 6200301 | Pfeiffer et al. | Mar 2001 | B1 |
| 6273874 | Parris | Aug 2001 | B1 |
| 6304766 | Colvin, Jr. | Oct 2001 | B1 |
| 6319540 | Van Antwerp et al. | Nov 2001 | B1 |
| 6363273 | Mastrorio et al. | Mar 2002 | B1 |
| 6370406 | Wach et al. | Apr 2002 | B1 |
| 6375627 | Mauze | Apr 2002 | B1 |
| 6464849 | Say et al. | Oct 2002 | B1 |
| 6544212 | Galley et al. | Apr 2003 | B2 |
| 6584335 | Haar et al. | Jun 2003 | B1 |
| 6585665 | Chapman et al. | Jul 2003 | B1 |
| 6602702 | McDevitt et al. | Aug 2003 | B1 |
| 6623490 | Crane et al. | Sep 2003 | B1 |
| 6627177 | Singaram et al. | Sep 2003 | B2 |
| 6653141 | Singaram et al. | Nov 2003 | B2 |
| 6663595 | Spohn et al. | Dec 2003 | B2 |
| 6702972 | Markle | Mar 2004 | B1 |
| 6711423 | Colvin | Mar 2004 | B2 |
| 6766183 | Walsh et al. | Jul 2004 | B2 |
| 6794195 | Colvin, Jr. | Sep 2004 | B2 |
| 6800451 | Daniloff et al. | Oct 2004 | B2 |
| 6804544 | Van Antwerp et al. | Oct 2004 | B2 |
| D525632 | Jost et al. | Jul 2006 | S |
| 7181260 | Gutierrez | Feb 2007 | B2 |
| D544871 | Lim et al. | Jun 2007 | S |
| 7226414 | Ballerstadt | Jun 2007 | B2 |
| 7229450 | Chitre et al. | Jun 2007 | B1 |
| D550242 | Niijima | Sep 2007 | S |
| D550245 | Niijima | Sep 2007 | S |
| 7277740 | Rohleder et al. | Oct 2007 | B2 |
| D559264 | Niijima | Jan 2008 | S |
| D560224 | Park et al. | Jan 2008 | S |
| 7353055 | Hogan | Apr 2008 | B2 |
| 7358094 | Bell et al. | Apr 2008 | B2 |
| 7381938 | Kobayashi et al. | Jun 2008 | B2 |
| 7390462 | Rao et al. | Jun 2008 | B2 |
| 7417164 | Suri | Aug 2008 | B2 |
| D580950 | Steele et al. | Nov 2008 | S |
| D582939 | Neuhaus | Dec 2008 | S |
| 7470420 | Singaram et al. | Dec 2008 | B2 |
| D592223 | Neuhaus | May 2009 | S |
| 7615007 | Shults et al. | Nov 2009 | B2 |
| D610065 | Gallert | Feb 2010 | S |
| 7751863 | Markle et al. | Jul 2010 | B2 |
| D626143 | Karten et al. | Oct 2010 | S |
| 7824918 | Suri | Nov 2010 | B2 |
| 7829341 | Gamsey et al. | Nov 2010 | B2 |
| 7879024 | Thorstenson et al. | Feb 2011 | B2 |
| 7939664 | Gamsey et al. | May 2011 | B2 |
| 8178676 | Gamsey et al. | May 2012 | B2 |
| 8202731 | Suri | Jun 2012 | B2 |
| 20020018843 | Van Antwerp et al. | Feb 2002 | A1 |
| 20020026108 | Colvin, Jr. | Feb 2002 | A1 |
| 20020193672 | Walsh et al. | Dec 2002 | A1 |
| 20030013974 | Natarajan et al. | Jan 2003 | A1 |
| 20030028089 | Galley et al. | Feb 2003 | A1 |
| 20040028612 | Singaram et al. | Feb 2004 | A1 |
| 20040072358 | Ballerstadt | Apr 2004 | A1 |
| 20040136924 | Boyd et al. | Jul 2004 | A1 |
| 20040219535 | Bell et al. | Nov 2004 | A1 |
| 20040260158 | Hogan | Dec 2004 | A1 |
| 20040260162 | Rohleder et al. | Dec 2004 | A1 |
| 20040267203 | Potter et al. | Dec 2004 | A1 |
| 20050054975 | Patel et al. | Mar 2005 | A1 |
| 20050090014 | Rao et al. | Apr 2005 | A1 |
| 20050130249 | Parris et al. | Jun 2005 | A1 |
| 20050233465 | Miller | Oct 2005 | A1 |
| 20050241959 | Ward et al. | Nov 2005 | A1 |
| 20050267326 | Loeb et al. | Dec 2005 | A1 |
| 20060083688 | Singaram et al. | Apr 2006 | A1 |
| 20060084854 | Cho et al. | Apr 2006 | A1 |
| 20060105174 | Aller et al. | May 2006 | A1 |
| 20060189863 | Peyser et al. | Aug 2006 | A1 |
| 20060189979 | Esch et al. | Aug 2006 | A1 |
| 20060195042 | Flaherty | Aug 2006 | A1 |
| 20060287600 | McEowen | Dec 2006 | A1 |
| 20070060872 | Hall et al. | Mar 2007 | A1 |
| 20070100356 | Lucatero et al. | May 2007 | A1 |
| 20070123775 | Meyer et al. | May 2007 | A1 |
| 20070175828 | Goedje et al. | Aug 2007 | A1 |
| 20070256477 | Moor | Nov 2007 | A1 |
| 20080001091 | Kobayashi et al. | Jan 2008 | A1 |
| 20080009687 | Smith et al. | Jan 2008 | A1 |
| 20080086042 | Brister et al. | Apr 2008 | A1 |
| 20080154107 | Jina | Jun 2008 | A1 |
| 20080183061 | Goode et al. | Jul 2008 | A1 |
| 20080187655 | Markle et al. | Aug 2008 | A1 |
| 20080188722 | Markle et al. | Aug 2008 | A1 |
| 20080188725 | Markle et al. | Aug 2008 | A1 |
| 20080305009 | Gamsey et al. | Dec 2008 | A1 |
| 20080305506 | Suri | Dec 2008 | A1 |
| 20090018418 | Markle et al. | Jan 2009 | A1 |
| 20090061528 | Suri | Mar 2009 | A1 |
| 20090081803 | Gamsey et al. | Mar 2009 | A1 |
| 20090177143 | Markle et al. | Jul 2009 | A1 |
| 20090264719 | Markle et al. | Oct 2009 | A1 |
| 20090275815 | Bickoff et al. | Nov 2009 | A1 |
| 20100274110 | Markle | Oct 2010 | A1 |
| 20100279424 | Suri | Nov 2010 | A1 |
| 20100312483 | Peyser | Dec 2010 | A1 |
| 20110077477 | Romey | Mar 2011 | A1 |
| 20110105866 | Markle | May 2011 | A1 |
| 20110152658 | Peyser | Jun 2011 | A1 |
| 20110171742 | Gamsey | Jul 2011 | A1 |
| 20110224516 | Romey et al. | Sep 2011 | A1 |
| 20110263953 | Markle | Oct 2011 | A1 |
| 20120053427 | Markle | Mar 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 85108331 | Jun 1987 | CN |
| 7707425 | Feb 1980 | CS |
| 3036868 | May 1982 | DE |
| 3509262 | Mar 1985 | DE |
| 3720736 | Jan 1989 | DE |
| 195 02 183 | Aug 1996 | DE |
| 298 17 986 | Feb 1999 | DE |
| 198 20 808 | Nov 1999 | DE |
| 0 073 558 | Mar 1983 | EP |
| 0 147 168 | Jul 1985 | EP |
| 0 617 977 | Feb 1994 | EP |
| 0 596 700 | May 1994 | EP |
| 0 758 451 | Jan 1999 | EP |
| 000760723-0001 | Jul 2007 | EP |
| 2217316 | Jul 2010 | EP |
| 2 222 686 | Aug 2010 | EP |
| 2 147 003 | Apr 2011 | EP |
| 2 054 476 | Jun 2011 | EP |
| 2 350 831 | Dec 1977 | FR |
| 2 624 007 | Jun 1989 | FR |
| 1 123 094 | Aug 1968 | GB |
| 1 447 163 | Aug 1976 | GB |
| 2 048 682 | Dec 1980 | GB |
| 53-68249 | Jun 1978 | JP |
| 54-13347 | Jan 1979 | JP |
| 54-111363 | Aug 1979 | JP |
| 54-155856 | Dec 1979 | JP |
| 56-116752 | Sep 1981 | JP |
| 56-116754 | Sep 1981 | JP |
| 58-162921 | Sep 1983 | JP |
| 3-52936 | Mar 1991 | JP |
| 1332866 | May 2008 | JP |
| 2009-544729 | Dec 2009 | JP |
| 2010-507711 | Mar 2010 | JP |
| 2010-517693 | May 2010 | JP |
| 2010-518397 | May 2010 | JP |
| 2010-526599 | Aug 2010 | JP |
| 2010-527010 | Aug 2010 | JP |
| 2010-535903 | Nov 2010 | JP |
| 2011-504399 | Feb 2011 | JP |
| 2011-511755 | Apr 2011 | JP |
| 5017377 | Jun 2012 | JP |
| 6216724 | Aug 1978 | SU |
| WO 8700920 | Feb 1987 | WO |
| WO 8804415 | Jun 1988 | WO |
| WO 9219150 | Nov 1992 | WO |
| WO 9622798 | Aug 1996 | WO |
| WO 9720530 | Jun 1997 | WO |
| WO 9737713 | Oct 1997 | WO |
| WO 9748437 | Dec 1997 | WO |
| WO 9808554 | Mar 1998 | WO |
| WO 0002048 | Jan 2000 | WO |
| WO 0246752 | Jun 2002 | WO |
| WO 03034047 | Apr 2003 | WO |
| WO 2004099778 | Nov 2004 | WO |
| WO 2005090014 | Apr 2005 | WO |
| WO 2005065241 | Jul 2005 | WO |
| WO 2006044973 | Apr 2006 | WO |
| WO 2007067743 | Jun 2007 | WO |
| WO 2008014280 | Jan 2008 | WO |
| WO 2008098011 | Aug 2008 | WO |
| WO 2008098087 | Aug 2008 | WO |
| WO 2008137604 | Nov 2008 | WO |
| WO 2008141241 | Nov 2008 | WO |
| WO 2008141243 | Nov 2008 | WO |
| WO 2009009756 | Jan 2009 | WO |
| WO 2009018426 | Jan 2009 | WO |
| WO 2009021057 | Feb 2009 | WO |
| WO 2009067626 | May 2009 | WO |
| WO 2009129186 | Oct 2009 | WO |
| WO 2010141888 | Sep 2010 | WO |
| WO 2011056274 | May 2011 | WO |
| WO 2011075710 | Jun 2011 | WO |
| WO 2011075711 | Jun 2011 | WO |
| WO 2011084713 | Jul 2011 | WO |
| WO 2011137178 | Nov 2011 | WO |
| Entry |
|---|
| PCT International Search Report re PCT/US2010/044761 dated Oct. 6, 2010. |
| Zhujun, Z., et al. (1984). Analytical Chimica Acta 160:305-309. |
| Agayn, V. I. and Dr. R. Walt (1993). “Fiber-optic sensor for continuous monitoring of fermentation pH.” Biotechnology 72(6):6-9. |
| Angel, S. M., “Optrodes: Chemically Selective Fiber Optic Sensors,” Spectoscopy, Apr. 1987, pp. 38-47. |
| Badugu R., et al.: “Wavelength-ratiometric near-physiological pH sensors based on 6-aminoquinolinium boronic acid probes” Talanta, Elsevier, Amsterdam, NL, vol. 66, No. 3, Apr. 30, 2005, pp. 569-574, XP004906383 ISSN: 0039-9140, cited in application abstract, conclusion p. 574. |
| Badugu, R. et al. “Boronic acid fluorescents ensors for monosaccharide signaling based on the 6-methoxyquinolinium heterocyclic nucleus: progress toward noninvasive and continuous glucose monitoring.” 2005 Bioorg. Med. Chem. 13 (1):113-119. |
| Badugu, R. et al. “Fluorescence sensors for monosaccharides based on the 6-methylquinoliniurn nucleus and boronic acid moiety: potential application to ophthalmic diagnostics.” 2005 Talanta 65 (3):762-768. |
| Bean & Johnson, 54 J. Am. Chem. Soc. 4415 (1932). |
| Burnett, Peebles & Hageman, 96 Biochemical and Biophysical Research Communications 157 (1980). |
| Cappuccio, F.E. et al. 2004 “Evaluation of pyranine derivatives in boronic acid based saccharide sensing: Significance of charge interaction between dye and quencher in solution and hydrogel” Journal of Fluorescence 14:521-533. |
| Cordes, D.B., et al.: “Two-component optical sugar sensing using boronic acid-substituted viologens with anionic fluorescent dyes-Modulated quenching with viologens as a method for monosaccharide detection”, Topics in Fluorescence Spectroscopy: vol. 11, Glucose Sensing 2006, Springer, pp. 47-87 (ISBN: 978-0-387-29571-8 p. 76, scheme 3.7). |
| Dawson, et al., 98 JACS 5996 (1970). |
| Definition of “cathether” from Webster's Ninth New Collegiate Dictionary, 1990, p. 216. |
| English Translation of DE 3,720,736. |
| EPO Office Action re App. No. 07 799 791.4 dated Jan. 29, 2010. |
| European Examination dated Apr. 1, 2010, re EP Application No. 08 769 266.1-1211. |
| European Examination Report re Application No. 08 755 267.5, dated Apr. 26, 2010. |
| Forster, “Intermolecular Energy Transfer and Fluorescence, Annaten der Physik” (1948) pp. 55-75. |
| Gamoh, et al., 222 Analytica Chimica Acta 201 (1989). |
| Gamsey, S. et al. 2007 “Boronic acid based bipyridinium salts as tunable receptors for monosaccharides and alpha-hydroxycarboxylates” J Am Chem Soc 129:1278-1286. |
| Gamsey, Soya et al.: “Continuous glulcose detection using boronic acid-substituted viologens in fluorescent hydrogels: linker effects and extension to fiber optics” Langmuir, ACS, Washington, DC vol. 22, No. 21, Oct. 10, 2006, pp. 9067-9074 (XP002442273 ISSN: 0743-7463, compound (1) schemata 1,2 figure 1). |
| Gehrich, J. L., D. W. Lubbers, et al. (1986). “Optical fluorescence and its application to an intravascular blood gas monitoring system.” IEE TBio-med Eng BME-33: 117-132. |
| Glazer, 59 Biochemistry 996 (1968). |
| Glazer, Chemical Abstracts, vol. 68, No. 111805q (1968). |
| Guilbault, George E., “Practical Fluorescence” (1973), pp. 599-600. |
| Hakkinen, Lajunen & Purokoski, A Potentiometric Study on the Complex Formation of Lactitol and Maltitol with Some Inorganic Oxyacids in Aqueous Solution, Chemical Abstracts, vol. 110, No. 83116f (1989). |
| Hakkinen, Purokoski & Lajunen, A Potentiometric Study on the Complex Formation of Germanic Acid and Germanate Ion with Sugar Acids and Disaccharides in Aqueous Solution, Chemical Abstracts, vol. 105, No. 233265s (1986). |
| Hayashi, et al., 149 Clinica Chimica Acta 149 (1985). |
| Hirata O. et al. 2002 “Allosteric saccharide sensing by a phenylboronic-acids-appended 5,15- bis(triarylethynyl)porphyrin” J Suprarnolecular Chemistry 2:133-142. |
| Hirshfeld, “Reabsorption Sensing in Fluorescence Spectroscopy,” UCRL Abstract No. 89736 ABST, published by Pittsberg Conference on Scientific Instrumentation, Mar. 1984. |
| Kirk-Othmer, Encyclopedia of Chemical Technology, 3rd ed., vol. 8, John Wiley and Sons, New York, pp. 201-203 (1979). |
| Kostov, Y., P. Harms, et al. (2001). “Low-cost microbioreactor for high-throughput bioprocessing.” Biotechnol Bioeng 72: 346-352. |
| Lakowitz et al., :“Optical sensing of glucose using phase-modulation fluorimtry,” Analytica Chimica Acta, 271, (1993), 155-164. |
| Lindner, et al., 473 J. Chromatography 227-240 (1989). |
| Lutty, G. A. (1978). “The acute intravenous toxicity of stains, dyes, and other fluorescent substances.” Toxical Pharmacol. 44: 225-229. |
| Meadows and Schultz, “Design, manufacture and characterization of an optical fiber glucose affinity sensor based on an homogeneous fluorescence energy transfer assay system,” (1993) Anal. Chim. Acta 280: pp. 21-30. |
| Medtronic, Features of the Guardian REAL-Time Continuous Glucose Monitoring System, Features that fit your diabetes management lifestyle, located at http://www.minimed.com/products/guardian/features.html on Aug. 28, 2007. |
| Mosbach, Methods in Enzymology, vol. XLIV, 53 (1976). |
| Niu C.G. et al. “Fluorescence ratiometric pH sensor prepared from covalently immobilized porphyrin and benzothioxanthen e.” 2005 Anal. Bioanal. Chem. 383(2):349-357. |
| Offenbacher, H., O. S. Wolfbeis, et al. (1986). “Fluorescence optical sensors for continuous determination of near-neutral pH values.” Sensor Actuator 9: 73-84. |
| PCT Application No. PCT/US2008/063330. |
| PCT Application No. PCT/US2008/063332. |
| PCT International Preliminary Report on Patentabilitu re PCT/US2008/063330 dated Nov. 10, 2009. |
| PCT International Preliminary Report on Patentability and Written Opinion re PCT/US2008/053097 dated Aug. 11, 2009. |
| PCT International Preliminary Report on Patentability and Written Opinion re PCT/US2008/072359, dated Feb. 9, 2010. |
| PCT International Search Report (Declaration of Non-Establishment of ISR) and Written Opinion re PCT/US2009/040379 dated Aug. 4, 2009. |
| PCT International Search Report and Written Opinion re PCT/US2008/052204, dated May 27, 2008. |
| PCT International Search Report and Written Opinion re PCT/US2008/053226, dated Oct. 15, 2008. |
| PCT International Search Report and Written Opinion re PCT/US2008/062303 dated Aug. 14, 2008. |
| PCT International Search Report and Written Opinion re PCT/US2008/063330 dated Sep. 3, 2008. |
| PCT International Search Report and Written Opinion re PCT/US2008/069855 dated Apr. 16, 2009. |
| PCT International Search Report and Written Opinion re PCT/US2008/072359 dated Dec. 15, 2008. |
| PCT International Search Report and Written Opinion re PCT/US2008/084239 dated Jan. 29, 2009. |
| PCT International Search Report re PCT/US2007/074255 dated Jul. 8, 2008 in 3 pages. |
| PCT International Search Report re PCT/US2008/053097 dated Jun. 27, 2008. |
| PCT Partial International Search Report re PCT/US2008/063332 dated Oct. 20, 2009. |
| PCT Partial International Search Report re PCT/US2008/072359 dated Oct. 15, 2008. |
| PCT Partial Search Report re PCT/US2008/053226 dated Jun. 27, 2008. |
| PCT Report on Patentability and Written Opinion re PCT/US2007/074255 dated Jan. 27, 2009 in 9 pages. |
| PCT Report on Patentability and Written Opinion re PCT/US2008/063332 dated Nov. 19, 2009. |
| Purokoski, Lajunen & Hakkinen, A Potentiometric Study on the Complex Formation of Arsenious Acid, Arsenite Ion, Telluric Acid and Tellurate Ion with Sugar Acids and Disaccharides in Aqueous Solution, Chemical Abstracts, vol. 107, No. 122178n (1987). |
| Roy, et al., J. Inorg. Nucl. Chem., 106 (1957). |
| Schulman, S. G., S. Chen, et al. (1995). “Dependence of the fluorescence of immobilized 1-hydroxypyrene-3,6,8-trisulfonate on solution pH: extension of the range of applicability of a pH fluorosensor.” Anal Chim Acta 304: 165-170. |
| Seitz, “Chemical Sensors Based on Fiber Optics,” Analytical Chemistry, vol. 56, pp. 16a-34a, 1984. |
| Sharrett, Z. et al. 2008 “Boronic acid-appended bis-viologens as a new family of viologen quenchers for glucose sensing” Tetrahedron Letters 49:300-304. |
| Snyder, et al., “The Preparation of Some Azo Boronic Acids,” 70 J. Am. Chem. Soc. 232 (1948). |
| Song, A., S. Parus, et al. (1997) “High-performance fiber-optic pH microsensors for practical physiological measurements using a dual-emission sensitive dye.” Analytical Chemistry 69: 863-867. |
| Streitwieser, Jr. & Heathcock, Introduction to Organic Chemistry (1976). |
| Sturdevant, M. F.: “How Sterilization Changes Long-Term Resin Properties”, Plastics Engineering, Jan. 1991, pp. 27-32. |
| Suri, J. T. et al. 2003 “Continuous glucose sensing with a fluorescent thin-film hydrogel” Angew Chem Int Ed 42:5857-5859. |
| The Immunoassay Handbook, pp. 1-618, ed. David Wild, Macmillan Press, 1994, United Kingdom. |
| Turner N.G. et al. “Determination of the pH Gradient Across the Stratum Corneum.” 1998 J. Investig. Dermatol. Symp. Proc. Aug. 3(2):110-3. |
| Udenfreund, “Fluorescence Assay in Biology and Medicine” (1962) pp. 108-109. |
| Van Kempien & Kreuzer, “A Single-Unit Carbon Dioxide Sensing Microelectrode System,” Respiration Physiology, (1975), 23, 371-379. |
| Vermeer, et al., 37 Tetr. Letters 3255 (1970). |
| Wang, D. et al. 2001 “Photoluminescence quenching of conjugated macromolecules by bipyridinium derivatives in aqueous media: charge dependence” Langmuir 17:1262-1266. |
| Wolfbeis, O. S., E. Fuerlinger, et al. (1983). “Fluorimetric analysis. I. Study on fluorescent indicators for measuring near neutral (‘physiological’) pH values.” Fresneius' Z. Anal. Chem. 314(2): 119-124. |
| Xu, Z., A. Rollins, et al. (1998) “A novel fiber-optic pH sensor incorporating carboxy SNAFL-2 and fluorescent wavelength-ratiometric detection” Journal of Biomedical Materials Research 39:9-15. |
| Zhang, S., S. Tanaka, et al. (1995). “Fibre-optical sensor based on fluorescent indicator for monitoring physiological pH values.” Med Biol Eng Comput 33: 152-156. |
| Zhujun, Z. and W. R. Seitz (1984). “A fluorescence sensor for quantifying pH in the range from 6.5 to 8.5.” Analytical Chimica Acta 160: 47-55. |
| EPO Exam Report re EP App. No. 08 728 399.0, dated Dec. 7, 2010. |
| European Examination Report dated Jan. 25, 2012, re EP Application No. 08 729 209.0. |
| European Examination Report dated Jul. 2, 2012, re EP Application No. 08 729 209.0. |
| European Examination Report dated May 11, 2010, re EP Application No. 08 729 209.0. |
| European Examination Report re App. No. 08 797 302.0, dated Jan. 24, 2011. |
| European Examination Report re App. No. 08 797 302.0, dated Nov. 7, 2011. |
| European Examination Report re Application No. 08 755 267.5, dated Sep. 14, 2010. |
| Japanese First Office Action, re JP Application No. 2009-549167, dated Nov. 29, 2011. |
| Japanese Office Action, re JP Application No. 2009-521962, dated Jul. 31, 2012. |
| Japanese Office Action, re JP Application No. 2010-507712, dated Jun. 15, 2012. |
| PCT International Preliminary Report and Written Opinion re PCT/US2009/040379 dated Oct. 19, 2010. |
| PCT International Preliminary Report on Patentability and Written Opinion date of Issuance Apr. 3, 2012. |
| PCT International Preliminary Report on Patentability and Written Opinion re PCT Application No. PCT/US2010/061169, dated Jun. 19, 2012. |
| PCT International Preliminary Report on Patentability and Written Opinion re PCT Application No. PCT/US2010/061173, dated Jun. 19, 2012. |
| PCT International Preliminary Report on Patentability re PCT/US201 0/037502, dated Dec. 6, 2011. |
| PCT International Search Report and Report on Patentability re PCT Application No. PCT/US2010/061163, dated (mailed) Jun. 28, 2012. |
| PCT International Search Report and Written Opinion in App. No. PCT/US2011/028222, dated May 6, 2011, 30 pages. |
| PCT International Search Report and Written Opinion re App. No. PCT/US 10/61163, dated Mar. 9, 2011. |
| PCT International Search Report and Written Opinion re App. No. PCT/US10/61169, dated Mar. 1, 2011. |
| PCT International Search Report and Written Opinion re App. No. PCT/US10/61173, dated Feb. 28, 2011. |
| PCT International Search Report and Written Opinion re PCT App. No. PCT/US 10/50910, dated Dec. 3, 2010. |
| PCT International Search Report and Written Opinion re PCT/US2010/037502, dated Aug. 6, 2010. |
| PCT International Search Report and Written Opinion re PCT/US2011/034167, mailed Jul. 29. 2011. |
| PCT Preliminary Report re PCT/US2008/084239 dated May 25, 2010. |
| PCT Search Report and Written Opinion re PCT/US2011/023939, dated Jul. 27, 2011. |
| Number | Date | Country | |
|---|---|---|---|
| 20110105866 A1 | May 2011 | US |
